82 FR 49662 - Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest

INTERNATIONAL TRADE COMMISSION

Federal Register Volume 82, Issue 206 (October 26, 2017)

Page Range		49662-49663
FR Document		2017-23233

Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled Certain Glucosylated Steviol Glycosides, and Products Containing Same, DN 3266; the Commission is soliciting comments on any public interest issues raised by the complaint or complainant's filing pursuant to the Commission's Rules of Practice and Procedure.

Federal Register, Volume 82 Issue 206 (Thursday, October 26, 2017)

[Federal Register Volume 82, Number 206 (Thursday, October 26, 2017)]
[Notices]
[Pages 49662-49663]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-23233]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION


Notice of Receipt of Complaint; Solicitation of Comments Relating 
to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has received a complaint entitled Certain Glucosylated 
Steviol Glycosides, and Products Containing Same, DN 3266; the 
Commission is soliciting comments on any public interest issues raised 
by the complaint or complainant's filing pursuant to the Commission's 
Rules of Practice and Procedure.

FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Secretary to the 
Commission, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-2000. The public version of 
the complaint can be accessed on the Commission's Electronic Document 
Information System (EDIS) at https://edis.usitc.gov, and will be 
available for inspection during official business hours (8:45 a.m. to 
5:15 p.m.) in the Office of the Secretary, U.S. International Trade 
Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 
205-2000.
    General information concerning the Commission may also be obtained 
by accessing its Internet server at United States International Trade 
Commission (USITC) at https://www.usitc.gov. The public record for this 
investigation may be viewed on the Commission's Electronic Document 
Information System (EDIS) at https://edis.usitc.gov. Hearing-impaired 
persons are advised that information on this matter can be obtained by 
contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint and 
a submission pursuant to Sec.  210.8(b) of the Commission's Rules of 
Practice and Procedure filed on behalf of PureCircle USA Inc. and 
PureCircle Sdn Bhd on October 20, 2017. The complaint alleges 
violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in 
the importation into the United States, the sale for importation, and 
the sale within the United States after importation of certain 
glucosylated steviol glycosides, and products containing same. The 
complaint names as respondents Sweet Green Fields USA LLC of 
Bellingham, WA; Sweet Green Fields Co., Ltd of Bellingham, WA; and 
Ningbo Green-Health Pharma-ceutical Co., Ltd. a/k/a NB Green-Health 
Pharma-ceutical Co., Ltd. of China. The complainant requests that the 
Commission issue a limited exclusion order, cease and desist orders, 
and impose a bond upon respondents' alleged infringing articles during 
the 60-day Presidential review period pursuant to 19 U.S.C. 1337(j).
    Proposed respondents, other interested parties, and members of the 
public are invited to file comments, not to exceed five (5) pages in 
length, inclusive of attachments, on any public interest issues raised 
by the complaint or Sec.  210.8(b) filing. Comments should address 
whether issuance of the relief specifically requested by the 
complainant in this investigation would affect the public health and 
welfare in the United States, competitive conditions in the United 
States economy, the production of like or directly competitive articles 
in the United States, or United States consumers.
    In particular, the Commission is interested in comments that:
    (i) Explain how the articles potentially subject to the requested 
remedial orders are used in the United States;
    (ii) identify any public health, safety, or welfare concerns in the 
United States relating to the requested remedial orders;
    (iii) identify like or directly competitive articles that 
complainant, its licensees, or third parties make in the United States 
which could replace the subject articles if they were to be excluded;
    (iv) indicate whether complainant, complainant's licensees, and/or 
third party suppliers have the capacity to replace the volume of 
articles potentially subject to the requested exclusion order and/or a 
cease and desist order within a commercially reasonable time; and
    (v) explain how the requested remedial orders would impact United 
States consumers.
    Written submissions must be filed no later than by close of 
business, eight calendar days after the date of publication of this 
notice in the Federal Register. There will be further opportunities for 
comment on the public interest after the issuance of any final initial 
determination in this investigation.
    Persons filing written submissions must file the original document 
electronically on or before the deadlines stated above and submit 8 
true paper copies to the Office of the Secretary by

[[Page 49663]]

noon the next day pursuant to Sec.  210.4(f) of the Commission's Rules 
of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer 
to the docket number (``Docket No. 3266'') in a prominent place on the 
cover page and/or the first page. (See Handbook for Electronic Filing 
Procedures, Electronic Filing Procedures \1\). Persons with questions 
regarding filing should contact the Secretary (202-205-2000).
---------------------------------------------------------------------------

    \1\ Handbook for Electronic Filing Procedures: https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf.
---------------------------------------------------------------------------

    Any person desiring to submit a document to the Commission in 
confidence must request confidential treatment. All such requests 
should be directed to the Secretary to the Commission and must include 
a full statement of the reasons why the Commission should grant such 
treatment. See 19 CFR 201.6. Documents for which confidential treatment 
by the Commission is properly sought will be treated accordingly. All 
such requests should be directed to the Secretary to the Commission and 
must include a full statement of the reasons why the Commission should 
grant such treatment. See 19 CFR 201.6. Documents for which 
confidential treatment by the Commission is properly sought will be 
treated accordingly. All information, including confidential business 
information and documents for which confidential treatment is properly 
sought, submitted to the Commission for purposes of this Investigation 
may be disclosed to and used: (i) By the Commission, its employees and 
Offices, and contract personnel (a) for developing or maintaining the 
records of this or a related proceeding, or (b) in internal 
investigations, audits, reviews, and evaluations relating to the 
programs, personnel, and operations of the Commission including under 5 
U.S.C. Appendix 3; or (ii) by U.S. government employees and contract 
personnel,\2\ solely for cybersecurity purposes. All nonconfidential 
written submissions will be available for public inspection at the 
Office of the Secretary and on EDIS.\3\
---------------------------------------------------------------------------

    \2\ All contract personnel will sign appropriate nondisclosure 
agreements.
    \3\ Electronic Document Information System (EDIS): https://edis.usitc.gov.
---------------------------------------------------------------------------

    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and of Sec. Sec.  
201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure 
(19 CFR 201.10, 210.8(c)).

    By order of the Commission.

    Issued: October 20, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-23233 Filed 10-25-17; 8:45 am]
BILLING CODE 7020-02-P

Federal Register / Vol. 82, No. 206 / Thursday, October 26, 2017 / Notices 49663

noon the next day pursuant to § 210.4(f) Issued: October 20, 2017. Research, Inc., #100 Carr 198, Industrial
of the Commission’s Rules of Practice Lisa R. Barton, Park, Juncos, Puerto Rico 00777–3873
and Procedure (19 CFR 210.4(f)). Secretary to the Commission. applied to be registered as an importer
Submissions should refer to the docket [FR Doc. 2017–23233 Filed 10–25–17; 8:45 am] of hydromorphone (9150), a basic class
number (‘‘Docket No. 3266’’) in a BILLING CODE 7020–02–P
of controlled substance in schedule II.
prominent place on the cover page and/ The company plans to import the
or the first page. (See Handbook for listed controlled substance in finished
Electronic Filing Procedures, Electronic DEPARTMENT OF JUSTICE dosage form for clinical trials, research
Filing Procedures 1). Persons with and analytical purposes.
questions regarding filing should Drug Enforcement Administration The import of this class of controlled
contact the Secretary (202–205–2000). substance will be granted only for
[Docket No. DEA–392] analytical testing, research, and clinical
Any person desiring to submit a
Importer of Controlled Substances trials. This authorization does not
document to the Commission in
Application: Galephar Pharmaceutical extend to the import of a finished FDA
confidence must request confidential approved or non-approved dosage form
treatment. All such requests should be Research, Inc.
for commercial sale.
directed to the Secretary to the
ACTION: Notice of application. Dated: October 18, 2017.
Commission and must include a full
statement of the reasons why the Demetra Ashley,
DATES: Registered bulk manufacturers of
Commission should grant such Acting Assistant Administrator.
the affected basic classes, and
treatment. See 19 CFR 201.6. Documents applicants therefore, may file written [FR Doc. 2017–23328 Filed 10–25–17; 8:45 am]
for which confidential treatment by the comments on or objections to the BILLING CODE 4410–09–P
Commission is properly sought will be issuance of the proposed registration on
treated accordingly. All such requests or before November 27, 2017. Such
should be directed to the Secretary to DEPARTMENT OF JUSTICE
persons may also file a written request
the Commission and must include a full for a hearing on the application on or Drug Enforcement Administration
statement of the reasons why the before November 27, 2017.
Commission should grant such ADDRESSES: Written comments should [Docket No. 17–28]
treatment. See 19 CFR 201.6. Documents be sent to: Drug Enforcement
for which confidential treatment by the Yoon H. Choi, M.D.; Decision and
Administration, Attention: DEA Federal
Commission is properly sought will be Order
Register Representative/DRW, 8701
treated accordingly. All information, Morrissette Drive, Springfield, Virginia On April 4, 2017, the Assistant
including confidential business 22152. All requests for hearing must be Administrator, Division of Diversion
information and documents for which sent to: Drug Enforcement Control, issued an Order to Show Cause
confidential treatment is properly Administration, Attn: Administrator, to Yoon H. Choi, M.D. (Respondent), of
sought, submitted to the Commission for 8701 Morrissette Drive, Springfield, Brockton, Massachusetts. The Show
purposes of this Investigation may be Virginia 22152. All requests for hearing Cause Order proposed the revocation of
disclosed to and used: (i) By the should also be sent to: (1) Drug Respondent’s DEA Certificate of
Commission, its employees and Offices, Enforcement Administration, Attn: Registration as a practitioner, on the
and contract personnel (a) for Hearing Clerk/LJ, 8701 Morrissette ground that he does not have authority
developing or maintaining the records Drive, Springfield, Virginia 22152; and to dispense controlled substances in
of this or a related proceeding, or (b) in (2) Drug Enforcement Administration, Massachusetts, the State in which he is
internal investigations, audits, reviews, Attn: DEA Federal Register registered with the Agency. Show Cause
and evaluations relating to the Representative/DRW, 8701 Morrissette Order, at 1.
programs, personnel, and operations of Drive, Springfield, Virginia 22152. As to the Agency’s jurisdiction, the
the Commission including under 5 SUPPLEMENTARY INFORMATION: The Show Cause Order alleged that
U.S.C. Appendix 3; or (ii) by U.S. Attorney General has delegated his Respondent holds DEA Certificate of
government employees and contract authority under the Controlled Registration No. BC6966381, which
personnel,2 solely for cybersecurity Substances Act to the Administrator of authorizes him to dispense controlled
purposes. All nonconfidential written the Drug Enforcement Administration substances in schedules II through V as
submissions will be available for public (DEA), 28 CFR 0.100(b). Authority to a practitioner, at the registered address
inspection at the Office of the Secretary exercise all necessary functions with of Steward Medical Group, One Pearl
and on EDIS.3 respect to the promulgation and Street, Suite 2200, Brockton,
This action is taken under the implementation of 21 CFR part 1301, Massachusetts. Id. The Show Cause
incident to the registration of Order alleged that this registration does
authority of section 337 of the Tariff Act
manufacturers, distributors, dispensers, not expire until August 31, 2018. Id.
of 1930, as amended (19 U.S.C. 1337),
importers, and exporters of controlled As to the substantive ground for the
and of §§ 201.10 and 210.8(c) of the
substances (other than final orders in proceeding, the Show Cause Order
Commission’s Rules of Practice and
connection with suspension, denial, or alleged that ‘‘[o]n January 5, 2017, the
Procedure (19 CFR 201.10, 210.8(c)).
revocation of registration) has been Commonwealth of Massachusetts Board
By order of the Commission. redelegated to the Assistant of Registration in Medicine indefinitely
ethrower on DSK3G9T082PROD with NOTICES

Administrator of the DEA Diversion suspended [his] medical license’’ and
1 Handbook for Electronic Filing Procedures:
Control Division (‘‘Assistant that ‘‘[t]his order remains in effect.’’ Id.
https://www.usitc.gov/documents/handbook_on_ Administrator’’) pursuant to section 7 of The Order thus alleged that Respondent
filing_procedures.pdf.
2 All contract personnel will sign appropriate
28 CFR part 0, appendix to subpart R. is ‘‘without authority to handle
nondisclosure agreements. In accordance with 21 CFR controlled substances in . . .
3 Electronic Document Information System 1301.34(a), this is notice that on August Massachusetts, the [S]tate in which [he
(EDIS): https://edis.usitc.gov. 2, 2017, Galephar Pharmaceutical is] registered,’’ that he is ‘‘required to

VerDate Sep<11>2014 17:29 Oct 25, 2017 Jkt 244001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\26OCN1.SGM 26OCN1

Document Created: 2018-10-25 10:13:48
Document Modified: 2018-10-25 10:13:48

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Lisa R. Barton, Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000. The public version of the complaint can be accessed on the Commission's Electronic Document Information System (EDIS) at https://edis.usitc.gov, and will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000.
FR Citation		82 FR 49662